^
    2d
    Novel Piperine derivatives containing substituted Benzamide fragments: Design, synthesis, anti-breast cancer activity, and mechanistic study on the PI3K/AKT/mTOR pathway. (PubMed, Bioorg Med Chem)
    Among the tested compounds, HupCi-12 showed a favorable low-micromolar antiproliferative profile against MDA-MB-231 and SKBR3 breast cancer cells, with activity comparable to Chidamide in selected cell lines...Consistent with this possibility, HupCi-12 reduced the phosphorylation levels of PI3K, AKT, and mTOR and modulated apoptosis-associated proteins by decreasing BCL2 and increasing BAX. Overall, these findings identify HupCi-12 as a representative bioactive compound in this series and support its further optimization and mechanistic validation in breast cancer models.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Epidaza (chidamide)
    2d
    Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy (clinicaltrials.gov)
    P1, N=6, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide)
    4d
    Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Epidaza (chidamide) • lisaftoclax (APG-2575)
    8d
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (clinicaltrials.gov)
    P2, N=50, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Jun 2031 | Trial primary completion date: Jun 2022 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Epidaza (chidamide) • carmustine
    8d
    A single-arm clinical trial of chidamide combined with reduced-dose R-CHOP in the treatment of newly diagnosed MYC/BCL2 double-expression diffuse large B-cell lymphoma (ChiCTR2600121682)
    P=N/A, N=40, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New trial • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • MYC rearrangement + BCL6 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    8d
    A prospective, single-center Phase I/II clinical study of golixitinib in combination with chidamide in systemic treated cutaneous T-cell lymphoma (ChiCTR2600120648)
    P=N/A, N=65, Recruiting, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    New trial
    |
    Xospata (gilteritinib) • Epidaza (chidamide)
    8d
    A single-arm, open-label, multicenter exploratory clinical trial of brentuximab vedotin combined with chidamide for the treatment of CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) patients (ChiCTR2600119766)
    P=N/A, N=33, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    8d
    Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, West China Hospital
    New P1 trial
    |
    Epidaza (chidamide)
    8d
    Chemotherapy and Cadonilimab combined with or without Chidamide as first-line treatment for advanced and metastatic biliary tract cancer (B-Elievable/SCOG-B004): A multi-cohort, exploratory, phase 2trial (ChiCTR2400087443)
    P2, N=78, Recruiting, The First affiliated hospital of Soochow university; The First affiliated hospital of Soochow university | Not yet recruiting --> Recruiting | N=52 --> 78
    Enrollment open • Enrollment change
    |
    gemcitabine • capecitabine • oxaliplatin • Epidaza (chidamide) • Kaitanni (cadonilimab)
    8d
    A Prospective, Cohort, Open Study of Immunoradiotherapy Combined with Cidarbenamide and PD-1 Monotherapy in the Backline Treatment of Advanced Solid Tumors (ChiCTR2300068737)
    P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67
    Enrollment open • Phase classification • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    9d
    Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. (PubMed, JAMA)
    MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. This trial is the first to demonstrate the benefit of an epigenetic modulator in DLBCL, offering a new first-line therapeutic approach dually targeting MYC and BCL2 oncoprotein for this high-risk population. ClinicalTrials.gov Identifier: NCT04231448.
    Clinical • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)